How INVIMA Regulates Stem Cell Therapy in Colombia

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia's equivalent to the FDA — the national body responsible for regulating medications, medical devices, and related health products, including aspects of cell therapy provision.

What INVIMA oversight actually covers

INVIMA regulates facility licensing, certain product and material standards, and general healthcare provider oversight within Colombia. This provides a real regulatory framework for clinics operating in this space — but it's a different thing entirely from INVIMA specifically approving a stem cell or exosome product for a particular clinical indication, which (as covered in our regulatory status guide) generally hasn't happened for most orthopedic and aesthetic applications.

What to ask a clinic about their regulatory standing

• Is your facility licensed and operating under current INVIMA requirements?
• What specific product sourcing and handling standards do you follow?
• Can you provide documentation of your facility's regulatory compliance?

Why this framework still matters even without specific product approval

Facility licensing and provider oversight provide real safety guardrails — sterile handling, provider credentialing, and general healthcare quality standards — even in a space where specific product approval for these indications hasn't been established. This distinction matters for understanding what regulatory oversight is actually protecting you from.

The bottom line

Understanding precisely what regulatory framework applies — and what it does and doesn't guarantee — is part of making an informed decision, not a reason to dismiss the field altogether.